Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges
Author:
Open Access
Abstract
Antiphospholipid syndrome (APS), first described in 1983, is a systemic autoimmune disorder characterized by recurrent arterial and venous thrombosis, pregnancy complications, and persistent antiphospholipid antibodies (aPL). Over four decades, significant advancements have been made in understanding APS pathogenesis, diagnostics, and treatment. Key discoveries include the development of standardized anticardiolipin antibody (aCL) assays, the identification of β2-glycoprotein I (β2GPI) as a critical cofactor, and the elucidation of the “two-hit” hypothesis, which explains thrombotic events through a combination of aPL-induced prothrombotic priming and secondary external triggers. Recent research has highlighted the roles of complement activation, neutrophil extracellular traps (NETs), and genetic predispositions shared with systemic lupus erythematosus (SLE). Innovations like the antiphospholipid score (aPL-S) and updated classification criteria, including the 2023 ACR/EULAR guidelines, have improved diagnostic precision and risk stratification. Despite these advances, challenges remain in assay standardization and addressing seronegative APS. Future directions emphasize the integration of multimodal biomarkers, precision diagnostics, and targeted therapies aimed at complement and NET pathways. These efforts aim to achieve individualized care, improving outcomes for APS patients through harmonized diagnostics, mechanistic therapeutics, and data-driven approaches. This review underscores the evolving understanding of APS and its potential for personalized management strategies.Keywords
This publication has 87 references indexed in Scilit:
- First‐Line, Non‐Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β2‐Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies TestsArthritis Care & Research, 2018
- Involvement of p38 MAPK in the up‐regulation of tissue factor on endothelial cells by antiphospholipid antibodiesArthritis & Rheumatism, 2005
- Significance of valine/leucine247 polymorphism of β2‐glycoprotein I in antiphospholipid syndrome: Increased reactivity of anti–β2‐glycoprotein I autoantibodies to the valine247 β2‐glycoprotein I variantArthritis & Rheumatism, 2005
- Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombinArthritis & Rheumatism, 2004
- Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulantArthritis & Rheumatism, 2000
- A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodiesArthritis & Rheumatism, 1999
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Antibodies to β2‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosusArthritis & Rheumatism, 1996
- β2‐Glycoprotein i reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndromeArthritis & Rheumatism, 1994
- BIOLOGICALLY FALSE POSITIVE SEROLOGIC TESTS FOR SYPHILISJAMA, 1952